Treatment trajectories and patterns following non-medical switching to biosimilar adalimumab in patients with hidradenitis suppurativa: a retrospective observational multicenter study from Saudi Arabia

Background Adalimumab is the first biologic approved for moderate-to-severe hidradenitis suppurativa (HS). Considering potential cost savings, real-world data evaluating the prescribing patterns following a switch from the originator in HS remain limited.Methods We conducted a retrospective multicen...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ahmed Alamer, Taibah AbuTaki, Shareefa Mohammed Alonaizi, Dalal Saadoun Alsaadoun, Mukhtar Alomar
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2026-12-01
Edice:	Future Science OA
Témata:	Hidradenitis suppurativa adalimumab biosimilar non-medical switching treatment escalation biologics real-world-study
On-line přístup:	https://www.tandfonline.com/doi/10.1080/20565623.2026.2694330
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!